Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update

A prolonged QT interval is an important risk factor for ventricular arrhythmias and sudden cardiac death. QT prolongation can be caused by drugs. There are multiple risk factors for drug-induced QT prolongation, including genetic variation. QT prolongation is one of the most common reasons for withdrawal of drugs from the market, despite the fact that these drugs may be beneficial for certain patients and not harmful in every patient. Identifying genetic variants associated with drug-induced QT prolongation might add to tailored pharmacotherapy and prevent beneficial drugs from being withdrawn unnecessarily. In this review, our objective was to provide an overview of the genetic background of drug-induced QT prolongation, distinguishing pharmacokinetic and pharmacodynamic pathways. Pharmacokinetic-mediated genetic susceptibility is mainly characterized by variation in genes encoding drug-metabolizing cytochrome P450 enzymes or drug transporters. For instance, the P-glycoprotein drug transporter plays a role in the pharmacokinetic susceptibility of drug-induced QT prolongation. The pharmacodynamic component of genetic susceptibility is mainly characterized by genes known to be associated with QT interval duration in the general population and genes in which the causal mutations of congenital long QT syndromes are located. Ethnicity influences susceptibility to drug-induced QT interval prolongation, with Caucasians being more sensitive than other ethnicities. Research on the association between pharmacogenetic interactions and clinical endpoints such as sudden cardiac death is still limited. Future studies in this area could enable us to determine the risk of arrhythmias more adequately in clinical practice.

[1]  A. Hofman,et al.  Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration , 2008, Pharmacogenetics and genomics.

[2]  H. Wellens,et al.  Chronic Amiodarone Evokes No Torsade de Pointes Arrhythmias Despite QT Lengthening in an Animal Model of Acquired Long-QT Syndrome , 2001, Circulation.

[3]  Stefan A. Mann,et al.  hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.

[4]  A. Hoes,et al.  Pharmacogenetics of drug‐induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data , 2006, Pharmacoepidemiology and drug safety.

[5]  Yan Guo,et al.  Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. , 2014, Journal of the American College of Cardiology.

[6]  Christian Gieger,et al.  Common variants at ten loci modulate the QT interval duration in the QTSCD Study , 2009, Nature Genetics.

[7]  John Sharkey,et al.  Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.

[8]  田中 俊典 National Center for Biotechnology Information (NCBI) , 2012 .

[9]  R. Berecz,et al.  QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations , 2004, Journal of psychopharmacology.

[10]  International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. , 2005, Federal register.

[11]  B. Stricker,et al.  Short-term QT variability markers for the prediction of ventricular arrhythmias and sudden cardiac death: a systematic review , 2014, Heart.

[12]  A. Daly,et al.  Genome-wide association studies in pharmacogenomics , 2010, Nature Reviews Genetics.

[13]  A. Daly,et al.  Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy , 2007, Clinical pharmacology and therapeutics.

[14]  Jan A. Kors,et al.  Common NOS1AP Variants Are Associated With a Prolonged QTc Interval in the Rotterdam Study , 2007 .

[15]  A. Hofman,et al.  Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. , 2007, Circulation.

[16]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Frank B Sachse,et al.  Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Newton-Cheh,et al.  Association of NOS1AP Genetic Variants With QT Interval Duration in Families From the Diabetes Heart Study , 2008, Diabetes.

[19]  D. Jonker,et al.  A Pharmacokinetic‐pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical QT Prolongation from Human Ether‐a‐go‐go‐related Gene Current Inhibition Data , 2005, Clinical pharmacology and therapeutics.

[20]  S. Potkin,et al.  A Thorough QTc Study of 3 Doses of Iloperidone Including Metabolic Inhibition Via CYP2D6 and/or CYP3A4 and a Comparison to Quetiapine and Ziprasidone , 2013, Journal of clinical psychopharmacology.

[21]  D. Tester,et al.  The Molecular Autopsy: Should the Evaluation Continue After the Funeral? , 2012, Pediatric Cardiology.

[22]  M. Horie,et al.  Latent Genetic Backgrounds and Molecular Pathogenesis in Drug-Induced Long-QT Syndrome , 2009, Circulation. Arrhythmia and electrophysiology.

[23]  A. Hofman,et al.  Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation , 2009, Pharmacogenetics and genomics.

[24]  A. Hofman,et al.  Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval , 2013, The Pharmacogenomics Journal.

[25]  Adam Kiezun,et al.  Exome sequencing and the genetic basis of complex traits , 2012, Nature Genetics.

[26]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[27]  Nancy F. Hansen,et al.  An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval. , 2014, American journal of human genetics.

[28]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[29]  G. Breithardt,et al.  Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients , 2004, Journal of Molecular Medicine.

[30]  A. Camm,et al.  Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. , 2014, British journal of clinical pharmacology.

[31]  R. Shah,et al.  Drug‐induced QT interval prolongation: does ethnicity of the thorough QT study population matter? , 2013, British journal of clinical pharmacology.

[32]  Thomas Lumley,et al.  Common variants at ten loci influence QT interval duration in the QTGEN Study , 2009, Nature Genetics.

[33]  M. Droździk,et al.  Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. , 2007, Pharmacological reports : PR.

[34]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[35]  D. Levy,et al.  QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: The Framingham Heart Study. , 2005, Heart rhythm.

[36]  A. Moss,et al.  Long QT Syndrome in African‐Americans , 2010, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[37]  Dan M Roden,et al.  Drug-induced long QT and torsade de pointes: recent advances , 2007, Current opinion in cardiology.

[38]  R. Owens QT Prolongation with Antimicrobial Agents , 2012, Drugs.

[39]  Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug Labels , 2016 .

[40]  Jun Li,et al.  [Association of 5-HT(2A) receptor polymorphism and attention deficit hyperactivity disorder in children]. , 2002, Zhonghua yi xue za zhi.

[41]  R. Virmani,et al.  Sudden cardiac death. , 1987, Human pathology.

[42]  Sadeq A. Quraishi,et al.  5 HT(3)-receptor antagonists and cardiac repolarization time in patients expressing a novel genetic target associated with baseline QTc interval abnormalities. , 2011, Journal of clinical anesthesia.

[43]  P. Kannankeril Understanding drug-induced torsades de pointes: a genetic stance. , 2008, Expert Opinion on Drug Safety.

[44]  P. Volders,et al.  Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. , 2006, Pharmacology & therapeutics.

[45]  A. Chakravarti,et al.  Associations between NOS1AP Single Nucleotide Polymorphisms (SNPs) and QT Interval Duration in Four Racial/Ethnic Groups in the Multi‐Ethnic Study of Atherosclerosis (MESA) , 2013, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[46]  R. Shah Drug‐induced prolongation of the QT interval: why the regulatory concern? , 2002, Fundamental & clinical pharmacology.

[47]  Gerasimos S Filippatos,et al.  Drug-induced long QT syndrome. , 2007, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[48]  Miya Nunotani,et al.  Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor? , 2013, Journal of Human Genetics.

[49]  Peilin Jia,et al.  Genome-wide association study of antipsychotic induced QTc interval prolongation , 2010, The Pharmacogenomics Journal.

[50]  Karen L. Mohlke,et al.  Fine-Mapping and Initial Characterization of QT Interval Loci in African Americans , 2012, PLoS genetics.

[51]  J. Shim,et al.  Combined Effects of Itraconazole and CYP2D6*10 Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Haloperidol in Healthy Subjects , 2006, Journal of clinical psychopharmacology.

[52]  J. Hsia,et al.  Normal standards for QT and QT subintervals derived from a large ethnically diverse population of women aged 50 to 79 years (the Women's Health Initiative [WHI]). , 2006, The American journal of cardiology.

[53]  D. Rao,et al.  Familial aggregation of QT‐interval variability in a general population: results from the NHLBI Family Heart Study , 2001, Clinical genetics.

[54]  D. Price Evans,et al.  Blood quinidine levels and cardiac effects in white British and Nigerian subjects. , 1982, British journal of clinical pharmacology.

[55]  A. Chakravarti,et al.  Associations between Genetic Variants in the NOS1AP (CAPON) Gene and Cardiac Repolarization in the Old Order Amish , 2007, Human Heredity.

[56]  C. January,et al.  Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. , 2004, American journal of physiology. Heart and circulatory physiology.

[57]  M. H. Ensom,et al.  Pharmacogenetics of Risperidone: A Systematic Review of the Clinical Effects of CYP2D6 Polymorphisms , 2013, The Annals of pharmacotherapy.

[58]  Dan M Roden,et al.  Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. , 2012, Journal of the American College of Cardiology.

[59]  T. Sakaeda,et al.  MDR1 genotype-related pharmacokinetics and pharmacodynamics. , 2002, Biological & pharmaceutical bulletin.

[60]  M. Horie,et al.  Drug-Induced Long-QT Syndrome Associated With a Subclinical SCN5A Mutation , 2002, Circulation.

[61]  F. Cappuccio,et al.  Variant of SCN5A Sodium Channel Implicated in Risk of Cardiac Arrhythmia , 2002, Science.

[62]  Kathleen F. Kerr,et al.  Impact of Ancestry and Common Genetic Variants on QT Interval in African Americans , 2012, Circulation. Cardiovascular genetics.

[63]  A. Hofman,et al.  Both decreased and increased heart rate variability on the standard 10-second electrocardiogram predict cardiac mortality in the elderly: the Rotterdam Study. , 1999, American journal of epidemiology.

[64]  Marylyn D. Ritchie,et al.  A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes , 2012, Circulation. Cardiovascular genetics.

[65]  D. Vlahov,et al.  Racial susceptibility for QT prolongation in acute drug overdoses. , 2014, Journal of electrocardiology.

[66]  D. Roden,et al.  Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. , 2005, Heart rhythm.

[67]  C. Valdivia,et al.  Drug‐induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine , 2006, British journal of pharmacology.

[68]  M. Polymeropoulos,et al.  Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia , 2009, Molecular Psychiatry.

[69]  J. Barhanin,et al.  Cardiac K+ channels and drug-acquired long QT syndrome. , 2000, Therapie.

[70]  Michael J Ackerman,et al.  Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. , 2003, Mayo Clinic proceedings.

[71]  E. Boerwinkle,et al.  Multiple Independent Genetic Factors at NOS1AP Modulate the QT Interval in a Multi-Ethnic Population , 2009, PloS one.

[72]  R. Berecz,et al.  QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients , 2002, Journal of psychopharmacology.

[73]  N. Fukui,et al.  Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia , 2014, The Pharmacogenomics Journal.

[74]  Dan M Roden,et al.  Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. , 2011, Heart rhythm.

[75]  R. Shah Pharmacogenetics in drug regulation: promise, potential and pitfalls , 2005, Philosophical Transactions of the Royal Society B: Biological Sciences.

[76]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.

[77]  Bo Wang,et al.  Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels. , 2014, JAMA internal medicine.

[78]  A. Paulussen,et al.  Pharmacogenomics and acquired long QT syndrome. , 2005, Pharmacogenomics.

[79]  Hiroshi Morita,et al.  The QT syndromes: long and short , 2008, The Lancet.

[80]  L. Toivonen,et al.  Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. , 2007, Heart rhythm.

[81]  E. Cartwright,et al.  Neuronal Nitric Oxide Synthase Signaling in the Heart Is Regulated by the Sarcolemmal Calcium Pump 4b , 2007, Circulation.

[82]  Sean Ekins,et al.  Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis , 2006, Pharmaceutical Research.

[83]  M. Malik,et al.  Electrocardiographic QTc Changes Due to Moxifloxacin Infusion , 2009, Journal of clinical pharmacology.

[84]  G. Ford,et al.  CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. , 2000, British journal of clinical pharmacology.

[85]  J. Tanus-Santos,et al.  Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6 , 2003, The Pharmacogenomics Journal.

[86]  P. Carrupt,et al.  Stereoselective Block of hERG Channel by (S)‐Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers , 2007, Clinical pharmacology and therapeutics.

[87]  L. Graham,et al.  Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives , 2013, Journal of Interventional Cardiac Electrophysiology.

[88]  M. Droździk,et al.  Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. , 2007, Pharmacological reports : PR.

[89]  J. Lépine,et al.  KCNH2 polymorphism and methadone dosage interact to enhance QT duration. , 2014, Drug and alcohol dependence.

[90]  J. Stephens,et al.  Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. , 2004, Heart rhythm.

[91]  Joao A. C. Lima,et al.  Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms , 2002, Nature.

[92]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[93]  James A. Clark,et al.  Impact of ABCB1 Allelic Variants on QTc Interval Prolongation , 2010, Clinical Cancer Research.

[94]  R. Altman,et al.  Genome Wide Analysis of Drug-Induced Torsades de Pointes: Lack of Common Variants with Large Effect Sizes , 2013, PloS one.

[95]  R. Owens QT prolongation with antimicrobial agents: understanding the significance. , 2004, Drugs.

[96]  P. C. Viswanathan,et al.  Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.

[97]  Christine E Garnett,et al.  Population Pharmacokinetic and Concentration—QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies , 2011, Journal of clinical pharmacology.

[98]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[99]  A. Shuldiner,et al.  Pharmacogenomics: Application to the Management of Cardiovascular Disease , 2011, Clinical pharmacology and therapeutics.

[100]  Christian Funck-Brentano,et al.  Digoxin pharmacokinetics and MDR1 genetic polymorphisms , 2003, European Journal of Clinical Pharmacology.

[101]  A. Hofman,et al.  Identification of a common variant at the NOS1AP locus strongly associated to QT-interval duration. , 2008, Human molecular genetics.

[102]  D. Roden,et al.  Polymorphisms in Beta‐Adrenergic Receptor Genes in the Acquired Long QT Syndrome , 2002, Journal of cardiovascular electrophysiology.

[103]  Kaori Ito,et al.  Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study , 2009, Journal of clinical pharmacology.

[104]  Christian Gieger,et al.  A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization , 2006, Nature Genetics.

[105]  M. Rieder,et al.  Novel Rare Variants in Congenital Cardiac Arrhythmia Genes are Frequent in Drug-induced Torsades de Pointes , 2012, The Pharmacogenomics Journal.

[106]  M. Tobin,et al.  Gender and effects of a common genetic variant in the NOS1 regulator NOS1AP on cardiac repolarization in 3761 individuals from two independent populations. , 2008, International journal of epidemiology.

[107]  D. Flockhart,et al.  Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. , 2007, British journal of clinical pharmacology.

[108]  J. Camm,et al.  Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pages. , 2012, British journal of clinical pharmacology.

[109]  Sumche Man,et al.  Normal values of the electrocardiogram for ages 16-90 years. , 2014, Journal of electrocardiology.

[110]  Johnf . Thompson,et al.  Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. , 2004, Journal of molecular and cellular cardiology.